Schmid, Ralph A.

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 129

A microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids

Ruppen, J., Cortes-Dericks, L., Marconi, E., Karoubi, G., Schmid, R. A., Peng, R., Marti, T. M., & Guenat, O. T. (2014) · Lab Chip

3D Printing in Biomedical ResearchMicrofluidic and Capillary Electrophoresis Applications

Cited by 105

PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact

Klaeser, B., Wiskirchen, J., Wartenberg, J., Weitzel, T., Schmid, R. A., Mueller, M. D., & Krause, T. (2010) · European Journal of Nuclear Medicine and Molecular Imaging

Medical Imaging Techniques and ApplicationsCancer Diagnosis and Treatment

Cited by 68

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer

Yang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., & Peng, R.-W. (2019) · Oncogenesis

Lung Cancer Treatments and MutationsEndoplasmic Reticulum Stress and Disease

Cited by 58

mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer

Liang, S.-Q., Bührer, E. D., Berezowska, S., Marti, T. M., Xu, D., Froment, L., Yang, H., Hall, S. R. R., Vassella, E., Yang, Z., et al. (2019) · Oncogene

PI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations

Cited by 55